Regeneron Pharmaceuticals v. Merus N.V.

  1. October 2, 2017

    IP Attys Back Regeneron Over Inequitable Conduct Finding

    Numerous intellectual property law organizations and lawyers are calling for the full Federal Circuit to review its panel decision affirming that a Regeneron Pharmaceuticals Inc. patent is unenforceable in part because of inequitable conduct of litigators during a later infringement case, arguing it could “seriously and negatively affect the course of patent prosecution.”

  2. September 13, 2017

    Full Fed. Circ. Urged To Review Inequitable Conduct Ruling

    Regeneron Pharmaceuticals Inc. asked the Federal Circuit on Tuesday for a full-court rehearing of its panel decision finding that its patent on a genetically modified mouse is unenforceable in part due to the inequitable conduct of litigators in its infringement case against Merus NV.

  3. August 2, 2017

    Patent Prosecutors Alarmed By Inequitable Conduct Ruling

    A Federal Circuit decision finding a Regeneron Pharmaceuticals Inc. patent unenforceable due to inequitable conduct based partly on the behavior of litigators in an infringement case has alarmed attorneys who seek patents, who said it is unfair to tarnish the reputation of patent prosecutors using the actions of others.

  4. July 27, 2017

    Fed. Circ. OKs Inequitable Conduct Ruling Against Regeneron

    The Federal Circuit said Thursday a Regeneron Pharmaceuticals Inc. patent for a genetically modified mouse was unenforceable because of the biotechnology company’s inequitable conduct at the patent office, upholding a lower court’s decision.